… all consecutive patients who received molnupiravir treatment and were subsequently
followed up at least 5 days after treatment initiation. We excluded from the analysis patients for …

… Moreover, as the total number of patients treated with molnupiravir is unknown, we were
not able to establish the occurrence rates of the events, but could only provide a frequency …

… In the meta-analysis, molnupiravir had a favourable safety profile in outpatients with
COVID-19 during the study period because it had little or no effect on the incidence of adverse …

… Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing …
SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile. …

… in the literature, treatment with all doses of molnupiravir had a profile of side effects and
adverse events that was not clinically limiting during the 5 days of treatment and follow-up …

… cases with relatively good safety profile; exhibiting a significant … Molnupiravir recently
granted the FDA emergency use authorization to treat mild to moderate COVID-19 patients …

… benefit of molnupiravir for the treatment of breakthrough … experience with molnupiravir for
the treatment of mild-to … As for safety, molnupiravir had an excellent tolerability profile, similar to …

… The use of molnupiravir to treat confirmed SARS-CoV-2 infection in vaccinated adults who
are at increased risk of an adverse outcomes when omicron was the dominant circulating …

… We identified patients with COVID-19 who received either molnupiravir (800 mg twice daily
for 5 days) or nirmatrelvir plus … Molnupiravir for oral treatment of COVID-19 in nonhospitalized …

… Even though the effectiveness of the molnupiravir treatment is … clinical trials which documented
molnupiravir effectiveness in preventing … profile to the list of molnupiravir assets [7,34,35]. …